NeurologyLive® Friday 5 — September 6, 2024

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Overviewing Encouraging Early-Stage Data on Mivelsiran, RNA Therapeutic for Alzheimer Disease: Sharon Cohen, MD, FRCPC

The medical director of the Toronto Memory Program at the University of Toronto provided an in-depth overview of results from an ongoing phase 1 study assessing mivelsiran as a treatment for patients with early-stage Alzheimer disease. [WATCH TIME: 8 minutes]

2: Insights on Biohaven’s New Phase 2/3 Trial of Potassium Inhibitor BHV-7000 for Treating Focal Epilepsy

Principal investigator Aliza Alter, MD, a pediatric neurologist at the Institute of Neurology in Livingston, New Jersey, provided commentary on a newly initiated phase 2/3 study assessing BHV-7000 as an antiseizure medication.

3: Potential of Advancing Neurofibromatosis Care With Investigational Mirdametinib

Jim Cassidy, MD, PhD, chief medical officer at SpringWorks Therapeutics, talked about how the prioritization of mirdametinib, a promising treatment for both adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

4: NeuroVoices: Crystal Proud, MD, on SMA Awareness Month, Advances in Research and Treatments

The director of neurology and neuromuscular medicine at the Children’s Hospital of the King’s Daughters in Norfolk, Virginia, provided clinical perspective on some of the improvements in the everyday life and care of patients with spinal muscular atrophy.

5: Ravulizumab Long-Term Data and Management of NMOSD

In episode 3 of the "Expert Insights on Novel NMOSD Treatments" video series, Michael Levy, MD, PhD, examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.